Switzerland's Pharvaris Q1 loss per share narrows

Pharvaris NV

12/05/2026 21:23

Overview

Switzerland biopharma's Q1 loss per share narrowed yr/yr

Company closed $132 mln offering, extending cash runway into 2028

Key Phase 3 trial data for lead drug expected in Q3 2026, NDA submission on-track for 1H 2026

Outlook

Pharvaris expects topline CHAPTER-3 Phase 3 data for deucrictibant XR in 3Q2026

Company plans NDA submission for deucrictibant IR for HAE on-demand treatment in 1H2026

Pharvaris expects cash runway to extend into 2028 after $132 mln offering

Result Drivers

CLINICAL PIPELINE PROGRESS - Co said ongoing late-stage trials and preparations for regulatory submissions drove operational focus

DISCIPLINED CAPITAL ALLOCATION - Co attributed financial discipline to prioritizing success of lead drug, supported by recent $132 mln raise

Company press release: ID:nGNXbDpSNw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-EUR 0.59


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Pharvaris NV is $43.50, about 45.2% above its May 11 closing price of $29.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)